Gene augmentation therapy successfully treats mice with complete congenital stationary night blindness (cCSNB), improving retinal function and visual acuity.
Gene therapy restored vision in mice with a rare congenital retinal disease, establishing the approach as viable for an ultra-rare disorder lacking current treatments.
This Gene Therapy study demonstrates that AAV-mediated gene augmentation successfully restores bipolar cell function and measurable visual acuity in cCSNB mice, a rare X-linked or autosomal recessive retinal channelopathy with no current treatment options. The results establish the therapeutic viability of gene augmentation in this ultra-rare congenital visual disorder and support IND-enabling studies.
What the study was
- Study design
- preclinical_in_vivo
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Gene Ther
Why it surfaced
cCSNB is an ultra-rare retinal channelopathy (TRPM1 or CACNA1F mutations) with high unmet need; Gene Therapy journal; successful murine proof-of-concept is the first step toward clinical translation; relevant to rare disease watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.